TherapeuticsMD (TXMD) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 Product Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
February 20, 2020 6:57 AM EST- 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Companys Financial Guidance -
- Full-Year 2019 Total Net Product Revenue of $34.1 Million at the Top End of Financial Guidance -
- Company Launched ANNOVERA, a Novel, Long-Lasting Contraceptive -
- Company Expects Full-Year 2020 Net Product Revenue of $90 Million to $110 Million -
- Conference Call Scheduled for 8:30 a.m. ET Today -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company,... More
